Indications
• Insulin-resistant type 2 diabetes(HOMA-IR≥3.0)
• Severe obesity(BMI≥35 kg/m²)
Extended Indications
• Non-alcoholic steatohepatitis(NASH,NAS score reduc- tion≥2 points)
• Diabetic peripheral neuropathic pain(VAS score reduc- tion≥30%)
Features &Clinical Trial Data
1 Microneedle Array Technology:91%delivery efficiency,pain-free(pain score 0.3/10).
2 Sustained Dual-Target Activation:Stable blood concentration over 168 hours,intradayglycemic variability reduced by 42%.
3 Multicenter Study (n=1,846):
• 36-week hepatic fat content reduction: 22.3% (MRI-PDFF confirmed).
• Discontinuation rate: 2.8%vs.11.6%in injection group(P<0.001).
4 Formulation Innovation:
24-month room-temperature storage (≤30℃ dryenvironment),no cold chain required.
